Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CPX-351 in poor risk AML patients

Fabio Guolo • 11 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, discusses the use of CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, in poor-risk acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fabio Guolo

1:25
Low bone marrow cellularity predicts hematologic AEs to CPX-351 in AML
Fabio Guolo • 10 Dec 2023
2:55
Post-transplant PD1 blockade plus autologous lymphocytes in R/R HL
Fabio Guolo • 10 Dec 2023
1:30
Evaluating the optimal duration of CPX-351 treatment & best timing for alloSCT consolidation in AML
Fabio Guolo • 10 Dec 2023
3:10
Novel AML treament approaches
Fabio Guolo • 10 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals